Cedar Grove Capital Management (“CGCM”) is proud to offer its advisory management services through its separately managed account structure. CGCM specializes in a multi-strategy investment approach with an emphasis on small caps and below companies, as well as managing an opportunistic short book and other special situations. If you’re interested in learning more, please visit www.cedargrovecm.com or view our public research www.cedargroveresearch.com.
All information provided herein by Cedar Grove Capital Management, LLC (“CGCM”) is for informational purposes only and does not constitute investment advice or an offer or solicitation to buy or sell an interest in a private fund or any other security. CGCM may change its views about or its investment positions in any of the securities mentioned in this document at any time, for any reason or no reason. CGCM may buy, sell, or otherwise change the form or substance of any of its investments. CGCM disclaims any obligation to notify the market of any such changes.
Hey everyone,
We had the pleasure of sitting down with one of our friends, Ashwin Sharma, who is a clinician based in the UK and has had extensive experience with telehealth companies.
We connected last year when he read my HIMS short report “HIMS: Napoleon Begins His March Towards Russia?”, which was a top 5 most-read report of ours. We’ve continued to stay in contact over the last half year or so, but I was finally able to bring him in for a public chat regarding the telehealth industry and HIMS specifically.
Take a look at the show notes below, as well as a link to our content and Ashwin's content. I only read two people’s work on GLP-1s religiously, and Ash is one of them, so I highly encourage you to at least check him out.
In this episode of The Investors Corner Podcast by Cedar Grove Capital Management, Chief Investment Officer Paul Cerro welcomes Ash Sharma, writer and founder of the GLP One Digest.
They discuss the evolution and future of telehealth, touching on topics such as consumer health behaviors, limitations and dark sides of telehealth services, and the business model of labs and diagnostics. They delve into the controversial practices within the industry, such as compounded treatments and ethical concerns. The conversation also covers international expansion of telehealth services, particularly in the UK market, and the challenges HIMS is facing with new product offerings.
Finally, they explore the importance of proactive versus reactive healthcare and the impact of technological advancements, such as wearable devices, in promoting healthy lifestyles.
00:00 Introduction and Guest Introduction
03:40 Telehealth Evolution and Market Impact
06:49 Limitations and Challenges of Telehealth
14:10 The Dark Side of Telehealth
23:02 Preventive vs. Reactive Healthcare
30:36 HIMS and Lab Biomarkers Discussion
35:18 The Cost of Medical Devices
36:03 Compounding Treatments and Business Strategies
37:34 Diagnostic Blood Tests and Health Anxiety
39:27 The Business of Biomarkers and Medications
41:35 Cancer Diagnostics and False Positives
45:53 New Product Releases: TRT, HRT, and Peptides
54:33 International Expansion and Market Challenges
59:46 Telehealth Industry Insights and HIMS Future
01:03:25 Concluding Thoughts and Recommendations
Cedar Grove Capital Management Fund: www.cedargrovecapitalmanagement.com
Cedar Grove Capital Management Research: www.cedargroveresearch.com
Paul Cerro Twitter: https://x.com/paulcerro
Fund Twitter: https://x.com/cedargrovecm
Ash Twitter: https://x.com/Ashwinreads
GLP-1 Digest: https://www.glp1digest.com/
Don’t forget, you can also find us on Spotify if you’d like to follow and not miss out on any other episodes.
As always, we appreciate your support of our work. If you have any questions, please make sure to message or comment below. If you think others would benefit from the research/commentary we release, we would greatly appreciate your sharing.
Until next time,
Paul Cerro | Cedar Grove Capital Management
Personal Twitter: @paulcerro
Fund Twitter: @cedargrovecm
Disclaimer: All information provided herein by Cedar Grove Capital Management, LLC (“Cedar Grove Capital”) is for informational purposes only and does not constitute investment advice or an offer or solicitation to buy or sell an interest in a private fund or any other security. An offer or solicitation of an investment in a private fund will only be made to accredited investors pursuant to a private placement memorandum and associated documents.
Cedar Grove Capital may change its views about or its investment positions in any of the securities mentioned in this document at any time, for any reason or no reason. Cedar Grove Capital may buy, sell, or otherwise change the form or substance of any of its investments. Cedar Grove Capital disclaims any obligation to notify the market of any such changes.
The enclosed material is confidential and not to be reproduced or redistributed in whole or in part without the prior written consent of Cedar Grove Capital. The information in this material is only current as of the date indicated and may be superseded by subsequent market events or for other reasons. Statements concerning financial market trends are based on current market conditions, which will fluctuate. Any statements of opinion constitute only current opinions of Cedar Grove Capital which are subject to change and which Cedar Grove Capital does not undertake to update. Due to, among other things, the volatile nature of the markets, and an investment in the fund/partnership may only be suitable for certain investors. Parties should independently investigate any investment strategy or manager, and should consult with qualified investment, legal and tax professionals before making any investment.